Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | GB226 |
Synonyms | |
Therapy Description |
Geptanolimab (GB226) is a monoclonal antibody that targets PD-1 (PDCD1) and inhibits binding of the PD-L1 (CD274) ligand, potentially resulting in enhanced anti-tumor immune response (PMID: 29932513, PMID: 33046518). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
GB226 | Geptanolimab|GB-226|GB 226|CBT501|CBT-501|Genolimzumab | Immune Checkpoint Inhibitor 149 PD-L1/PD-1 antibody 122 | Geptanolimab (GB226) is a monoclonal antibody that targets PD-1 (PDCD1) and inhibits binding of the PD-L1 (CD274) ligand, potentially resulting in enhanced anti-tumor immune response (PMID: 29932513, PMID: 33046518). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
CD274 positive | alveolar soft part sarcoma | not predictive | GB226 | Phase II | Actionable | In a Phase II trial (Gxplore-005), patients with CD274 (PD-L1)-positive (CPS >=1%) alveolar soft part sarcoma achieved an objective response rate (ORR) of 33.3% (4/12; 95% CI 9.9-65.1) and a disease control rate (DCR) of 83.3% (10/12; 95% CI 51.6-97.9) in response to Geptanolimab (GB226) treatment, which were not different from the 40.0% ORR (10/25; 95% CI 21.1-61.3) and 88.0% DCR (22/25; 95% CI 68.8-97.5) observed in CD274 (PD-L1)-negative (CPS <1%) patients (PMID: 33046518; NCT03623581). | 33046518 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|